Belite Bio (BLTE)

• Market cap: $1.94B
• 1 day: -2.06%
• 5 days: 1.78%
• 1 month: -16.64%
• 3 months: 30.24%
• 6 months: 29.14%
• Year to date: 46.87%
• 1 year: 36.85%
• 5 years: 493.01%
• 10 years: 493.01%

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 20

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

36% more funds holding

Funds holding: 11 [Q2] → 15 (+4) [Q3]

0.36% less ownership

Funds ownership: 0.62% [Q2] → 0.26% (-0.36%) [Q3]

57% less capital invested

Capital invested by funds: $8.57M [Q2] → $3.69M (-$4.88M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $100 59% upside
• Avg. target: $105 67% upside
• High target: $110 75% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target	75% upside $110	Buy Maintained	15 Nov 2024
HC Wainwright & Co. Yi Chen 40% 1-year accuracy 62 / 154 met price target	59% upside $100	Buy Maintained	13 Nov 2024